25 results
Thumbnail

D2.332 - First reported case of IgE-mediated food allergy to Tetragonia tetragonioides (New Zealand spinach)

Thumbnail

D2.337 - REMA Score Outperforms C-kit and Tryptase in Identifying Mast Cell Disorders in Hymenoptera Venom Allergy

Thumbnail

D2.347 - Filaggrin Mutation in a Patient with Ant Anaphylaxis: Case Report and Literature Review

Thumbnail

D2.333 - Glatiramer acetate: when immunomodulation is not enough

Thumbnail

D2.335 - Single-nucleotide polymorphisms in the Mas-related G protein-coupled receptor X2 alter in vitro cellular responses to specific drugs

Thumbnail

D2.336 - Risk of systemic reactions among school-age children sensitized to fish, crustaceans and molluscs

Thumbnail

D2.338 - Gaps in Adrenaline Autoinjector Education Among Patients at Risk of Anaphylaxis: A Cross-Sectional Study

Thumbnail

D2.340 - Improving Post-Anaphylaxis Referral Pathways in the Emergency Department: A Quality Improvement Initiative

Thumbnail

D2.341 - Comparative Evaluation of Diagnostic Criteria for Food Allergy–Induced Anaphylaxis: Accuracy, Clinical Applicability, and Validation

Thumbnail

D2.342 - Environmental Exposure Predicts Severity of Hymenoptera Venom Anaphylaxis Better Than Classical Biomarkers: Added Value of Component-Resolved Diagnostics

Thumbnail

D2.343 - Anaphylactic Reaction to Methylprednisolone Acetate in a Young Adult

Thumbnail

D2.344 - National Data on Anaphylaxis in Brazil: Findings from the Brazilian Registry

Thumbnail

D2.345 - Successful Desensitization in a Pediatric Patient Who Developed an Immediate-Type Systemic Hypersensitivity Reaction to FVIII/vWF Concentrate

Thumbnail

D2.346 - When cold triggers anaphylaxis

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study